Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

In the market for a deal on a new car? If you can stretch to £300 per month, you’ll have a veritable treasure trove of finance deals to pick from. The sheer number of models that fall into this range ...

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...

Found the MG ZS of your dreams? Now you want to know all about it! With the help of Parkers, you can find out all of the key specs about the MG ZS from fuel efficiency in MPG and top speed in MPH, to ...

The Royal Enfield Bullet 350 holds a special place in the segment due to its retro design, rich heritage, and reliability. The Bullet 350 is built on an all-new chassis to contain RE's new J ...